Switching to Etanercept in Intestinal Behcet's Disease Complicated by Secondary Non-response to Anti-TNF-alpha Antibodies.
10.4078/jrd.2012.19.6.355
- Author:
Sunggun LEE
1
;
Tae Oh KIM
;
Chan Sun PARK
;
Hyun Kuk KIM
;
Seong Ho KIM
Author Information
1. Division of Rheumatology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea. junjan@paik.ac.kr
- Publication Type:Case Report
- Keywords:
Behcet's disease;
Intestinal;
Etanercept
- MeSH:
Antibodies;
Antibodies, Monoclonal;
Antibodies, Monoclonal, Humanized;
Arthritis, Rheumatoid;
Female;
Humans;
Immunoglobulin G;
Receptors, Tumor Necrosis Factor;
Recurrence;
Adalimumab;
Infliximab;
Etanercept
- From:Journal of Rheumatic Diseases
2012;19(6):355-358
- CountryRepublic of Korea
- Language:English
-
Abstract:
The efficacy of anti-TNF-alpha antibodies including infliximab and adalimumab for refractory intestinal Behcet's disease has recently been demonstrated in a series of case reports. The efficacy of switching to a different kind of anti-TNF-alpha agent in the face of refractoriness to one kind of anti-TNF-alpha agent, a common practice of proven efficacy in rheumatoid arthritis, has yet not been reported for intestinal Behcet's disease. In the present study, we report a case of 52-year-old female patient with intestinal Behcet's disease, who lost initial good response to infliximab, and was refractory to subsequent administrations of adalimumab. Her recent relapse of intestinal lesions could be successfully treated with etanercept. This case suggests that switching to etanercept might be a reasonable therapeutic option in case of intestinal Behcet's disease with secondary non-response to anti-TNF-alpha antibodies that is most likely to be mediated by anti-drug antibody.
